Skip to main content
SpringerLink
Log in

The Relationship Between Physicians and the Pharmaceutical Industry: Ethical Problems with the Every-Day Conflict of Interest

  • Published:
HEC Forum Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCES

  1. Wolfe SM. Why do American drug companies spend more than $12 billion a year pushing drugs? Is it education or promotion? Characteristics of materials distributed by drug companies: four views. Journ. Gen Int Med, 1996; 11: 637–639.

    Google Scholar 

  2. Hoffenberg R. The relationship between physicians and the pharmaceutical industry: A report of the Royal College of Physicians. Journ. R Coll Phys London, 1986; 20: 235–242.

    Google Scholar 

  3. McMurray RJ. Gifts to physicians from industry. Journal of the American Medical Association, 1991; 265: 501.

    Google Scholar 

  4. Coyle SL. Physician-industry relations. Part 1: individual physicians[position paper]. Annals of Internal Medicine, 2002; 136: 396–402.

    Google Scholar 

  5. Coyle SL. Physician-industry relations. Part 2: organizational issues[position paper]. Annals Internal Medicine, 2002; 136: 403–406.

    Google Scholar 

  6. Orlowski JP, Wateska l. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest, 1992; 102: 270–273.

    Google Scholar 

  7. Lichstein PR, Turner RC, O'Brien K. Impact of pharmaceutical representatives on internal medicine residency programs: A survey of residency program directors. Archives of Internal Medicine, 1992; 152: 1009–1013.

    Google Scholar 

  8. Bank JW III, Mainous AG III. Attitudes of medical school faculty towards gifts from the pharmaceutical industry. Acad. Med. 1992; 67: 610–612.

    Google Scholar 

  9. Goldfinger SE. A matter of influence. New England Journal of Medicine, 1987; 316: 1408–1409.

    Google Scholar 

  10. Reeder DO, Doughterty L, White LS. Pharmaceutical representatives and emergency medicine residents: A national survey. Annals of Emergency Medicine, 1993; 22: 1583–1586.

    Google Scholar 

  11. Lexchin J. Interactions between physicians and the pharmaceutical industry: What does the literature say? CMAJ, 1993: 1401–1407.

  12. Wanza, A. Physician and the pharmaceutical industry: Is a gift ever just a gift? Journal of the American Medical Association, 2000; 283: 373–380.

    Google Scholar 

  13. Kessler DA. Drug promotion and scientific exchange: The role of the clinical investigator. New England Journal of Medicine, 1991; 325: 201–203.

    Google Scholar 

  14. Relman AS. The Health care industry: Where is it taking us? New England Journal of Medicine, 1991; 325: 854–859.

    Google Scholar 

  15. Choudry NK, Stelfox HT, Detsky AS. Relationship between authors of clinical practice guidelines and the pharmaceutical industry. Journal of the American Medical Association, 2002; 287: 612–617.

    Google Scholar 

  16. Eichenwald K, Kolata G. Drug trials hide conflicts for doctors. NY Times. May 16, 1999; 148–51, 524: 1.

  17. Reich WT; ed. Codes. Encyclopedia of bioethics, revised edition. New York: Simon & Schuster; 1995: 2633–2649.

  18. Pellegrino ED, Thomasma DC. A philosophical basis of medical practice. New York: Oxford University Press: 1981; 196–219.

    Google Scholar 

  19. Jonsen AR. Watching the doctor. New England Journal of Medicine, 1983; 308: 1531–155.

    Google Scholar 

  20. Bricker EM. Industrial marketing and medical ethics. New England Journal of Medicine, 1989; 320: 1690–1692.

    Google Scholar 

  21. Peppin JF. Pharmaceutical sales representatives and physicians: Ethical considerations of a relationship. Journal of Medicine and Philosophy, 1996; 21: 83–96.

    Google Scholar 

  22. Peppin JF. An Engelhardtian analysis of interactions between pharmaceutical sales representatives and physicians. Journal of Medicine and Philosophy, 1997; 623–641.

  23. Medical Knowledge Self Assessment Program 11. General Internal Medicine section and Infectious Disease Section, 1998. 127, 228–229.

  24. Sixth report of the National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Archives of Internal Medicine, 1997; 156: 2413–2446.

    Google Scholar 

  25. Chren MM, Landefeld S. Murray TH. Doctors, drug companies, and gifts. Journal of the American Medical Association, 1989; 262: 3448–3451.

    Google Scholar 

  26. Camenisch PF. Gift and gratitude in ethics. Journal of Religious Ethics, 1981; 9: 1–33.

    Google Scholar 

  27. Guyatt G. Health sciences and the pharmaceutical industry: Partnerships can be effective and ethical. CMAJ, 1994; 151: 1323–1325.

    Google Scholar 

  28. Wright SM, Kern DE, Kolodner K, Howard DM, Brancati FL. Attributes of Excellent attending-physician role models. New England Journal of Medicine, 1998; 339: 1986–1993.

    Google Scholar 

  29. Schwartz TB. Drug company marketing in the groves of academic. West Journ. Med., 1992; 156: 660–661.

    Google Scholar 

  30. Bickell NA. Drug companies and continuing medical education. Journ. Gen Int Med., 1995; 10: 392–394.

    Google Scholar 

  31. Guyatt G. Development of residency program guidelines for interaction with the Pharmaceutical industry. CMAJ, 1993; 149: 405–408.

    Google Scholar 

  32. Westfall JM, McCabe J, Nicholas RA. Personal use of drug samples by physicians and office staff. Journal of the American Medical Association, 1997; 278: 141–143.

    Google Scholar 

  33. Rawlins MD. Doctors and the drug makers. Lancet, 1984; 276–9.

  34. Woollard RF. Addressing the pharmaceutical industry's influence on professional behavior. CMAJ, 1993; 149: 403–404.

    Google Scholar 

  35. Pellegrino ED, Thomasma DC. The virtues in medical practice. New York: Oxford University; 1993; 144–159.

    Google Scholar 

  36. Angell M. The doctor as double agent. Kennedy Institute of Ethics Journal, 1993; 3: 279–286.

    Google Scholar 

  37. Donaldson T. The social contract: norms for corporate conscience. In: Hoffman WM, Mills Marr J; eds. Business ethics: Readings and cases in corporate morality, second ed. New York: McGraw Hill; 1990.162–165.

    Google Scholar 

  38. Steinman MA. Gifts to physicians in the consumer marketing era. Journal of the American Medical Association, 2000; 284: 2243.

    Google Scholar 

  39. May WF. Money and the medical profession. Kennedy Institute of Ethics Journal, 1997; 7(1): 1–13.

    Google Scholar 

  40. Peabody FW. A medical classic: The care of the patient. Journal of the American Medical Association, 1984; 252:813–818.

    Google Scholar 

Download references

Authors
  1. Richard L. Allman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Allman, R.L. The Relationship Between Physicians and the Pharmaceutical Industry: Ethical Problems with the Every-Day Conflict of Interest. HEC Forum 15, 155–170 (2003). https://doi.org/10.1023/A:1024901008495

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1024901008495

Keywords

Search

Navigation